Predicted to enable several functions, including nuclear retinoic acid receptor binding activity; transcription coregulator activity; and transcription corepressor binding activity. Predicted to be a structural constituent of presynaptic active zone. Predicted to be involved in regulation of DNA-templated transcription; synaptic vesicle docking; and white fat cell differentiation. Predicted to act upstream of or within cellular response to leukemia inhibitory factor; positive regulation of retinoic acid receptor signaling pathway; and positive regulation of transcription by RNA polymerase II. Predicted to be located in ribbon synapse. Predicted to be part of transcription repressor complex. Predicted to be active in several cellular components, including photoreceptor ribbon synapse; presynaptic active zone cytoplasmic component; and presynaptic cytosol. Orthologous to human CTBP2 (C-terminal binding protein 2); PARTICIPATES IN chronic myeloid leukemia pathway; Notch signaling pathway; Wnt signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 3,4-methylenedioxymethamphetamine; 6-propyl-2-thiouracil.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA
[Fluorouracil co-treated with irinotecan] results in decreased expression of CTBP2 mRNA and CTBP2 protein affects the susceptibility to [Fluorouracil co-treated with irinotecan analog]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTBP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTBP2 mRNA
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CTBP2 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA
[Fluorouracil co-treated with Irinotecan] results in decreased expression of CTBP2 mRNA and CTBP2 protein affects the susceptibility to [Fluorouracil co-treated with Irinotecan analog]
Pyruvic Acid inhibits the reaction [CTBP1 protein binds to CTBP2 protein] and Pyruvic Acid promotes the reaction [CTBP2 protein binds to CYP17A1 promoter]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTBP2 mRNA
contains an A domain specific for ribbons, and a B domain identical with CtBP2, a transcriptional repressor that in turn is related to 2-hydroxyacid dehydrogenases